Aortic stiffness and cardiovascular risk in type 2 diabetes

Journal of Hypertension

Volumn 31, Issue 8, 2013, Pages 1584-1592

  Mansour, Abdellah Salah ^a   Yannoutsos, Alexandra ^b   Majahalme, Nilla ^b   Agnoletti, Davide ^b   Safar, Michel E ^b   Ouerdane, Said ^a   Blacher, Jacques ^b  

^a Nedir University Hospital   (Algeria)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

aortic stiffness; atherosclerosis; cardiovascular disease; cardiovascular risk assessment; cardiovascular risk factors; carotid femoral pulse wave velocity; type 2 diabetes

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ORAL ANTIDIABETIC AGENT;

ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; DIABETIC DIET; DIABETIC PATIENT; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PULSE PRESSURE; QUESTIONNAIRE; WAIST CIRCUMFERENCE;

EID: 84880533063     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283613074     Document Type: Article

References (47)

1. Safar ME, Temmar M, Kakou A, Lacolley P, Thornton SN. Sodium intake and vascular stiffness in hypertension. Hypertension 2009; 54:203-209.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
3. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000; 102:1014-1019.
4. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men. Influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011; 171:404-410.
5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-412.
6. Bailey CJ, Day C. Glycaemic memory. Br J Diabetes Vasc Dis 2008; 8:242-247.
7. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al., Collaborative Group ADVANCE. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
8. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
9. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129-139.
10. Nilsson PM, Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjornsdóttir S. Swedish National Diabetes Register (NDR). Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR). Diabetes Metab 2009; 35:439-446.
11. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 2007; 30:1292-1293.
12. Franklin SS, Lopez VA, Wong ND, Mitchell GF, Larson MG, Vasan RS, Levy D. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation 2009; 119:243-250.
13. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007; 50:197-203.
14. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27:2588-2605.
15. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010; 121:505-511.
16. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37:1236-1241.
17. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent S. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39:10-15.
18. Laurent S, Katsahian S, Fassot C, Tropeano AI, Laloux B, Boutouyrie P. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34:1203-1206.
19. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99:2434-2439.
20. Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H, et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001; 12:2117-2124.
21. Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME. Aortic pulse wave velocity predicts cardiovascular mortality in subjects > 70 years of age. Arterioscler Thromb Vasc Biol 2001; 21:2046-2050.
22. Sutton-Tyrrell K, Najjar SS, Boudreau RM, VenkitachalamL, Kupelian V, Simonsick EM, et al. Health ABC Study. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well functioning older adults. Circulation 2005; 111:3384-3390.
23. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006; 113:657-663.
24. Shokawa T, Imazu M, Yamamoto H, Toyofuku M, Tasaki N, Okimoto T, et al. Pulse wave velocity predicts cardiovascular mortality: findings from the Hawaii-Los Angeles Hiroshima study. Circ J 2005; 69:259-264.
25. Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113:664-670.
26. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762.
27. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995; 26:485-490.
28. Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999; 33:1111-1117.
29. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 2002; 106:3143-3421.
30. American Diabetes Association. Peripheral arterial disease in people with diabetes (consensus statement). Diabetes Care 2003; 26:3333-3341.
31. Pencina MJ, D'Agnostino RB Sr, D'Agnostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-172.
32. SAS. Nonparametric comparison of areas under correlated ROC curves. http://support.sas.com/kb/25/017.html. [Accessed 14 June 2011].
33. Berglund L. Nonparametric comparison of areas under correlated ROC curves. Uppsala Clinical Research Center. www.ucr.uu.se/en/index.php/epistat/ program-code [Accessed 7 June 2011].
34. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121:293-298.
35. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008; 51:527-539.
36. Chen Y, Huang Y, Li X, Xu M, Bi Y, Zhang Y, et al. Association of arterial stiffness with HbA1c in 1000 type 2 diabetic patients with or without hypertension. Endocrine 2009; 36:262-267.
37. Benetos A, Adamopoulos C, Bureau JM, Temmar M, Labat C, Bean K, et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 2002; 105:1202-1207.
38. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension 2009; 54:1328-1336.
39. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55:1318-1327.
40. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106:2085-2090.
41. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28:88-136.
42. Safar ME, Blacher J, Pannier B, Guerin A, Marchais SJ, Guyonvarc'h PM, London GM. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39:735-738.
43. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
44. Chirinos JA, Zambrano JP, Chakko S, Veerani A, Schob A, Willens HJ, et al. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension 2005; 45:980-985.
45. Vlachopoulos C, Aznaouridis K, Stefanadis C. Clinical appraisal of arterial stiffness: the Argonauts in front of the Golden Fleece. Heart 2006; 92:1544-1550.
46. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in endstage renal failure. Circulation 2001; 103:987-992.
47. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.